Organon & Co. (NYSE:OGN) Reaches New 1-Year High – Here’s Why

Shares of Organon & Co. (NYSE:OGN) reached a new 52-week high during trading on Wednesday. The stock traded as high as $13.79 and last traded at $13.7750, with a volume of 2207764 shares changing hands. The stock had previously closed at $13.74.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, August 3rd. Five investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $11.40.

Organon & Co. Stock Performance

The firm has a market capitalization of $3.63 billion, a PE ratio of 17.93, a price-to-earnings-growth ratio of 1.28 and a beta of 1.55. The company has a debt-to-equity ratio of 8.43, a current ratio of 1.95 and a quick ratio of 1.44. The stock has a 50-day moving average price of $13.70 and a 200-day moving average price of $12.49.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, September 10th. Shareholders of record on Friday, August 14th were paid a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Friday, August 14th. Organon & Co.’s dividend payout ratio (DPR) is presently 10.39%.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Cetera Investment Advisers lifted its position in shares of Organon & Co. by 1.7% during the 1st quarter. Cetera Investment Advisers now owns 48,073 shares of the company’s stock worth $288,000 after buying an additional 788 shares during the period. Wedmont Private Capital grew its stake in Organon & Co. by 8.9% during the third quarter. Wedmont Private Capital now owns 10,954 shares of the company’s stock worth $151,000 after buying an additional 899 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Organon & Co. by 38.2% in the third quarter. GAMMA Investing LLC now owns 7,990 shares of the company’s stock valued at $109,000 after acquiring an additional 2,208 shares during the last quarter. Allied Private Wealth LLC bought a new stake in Organon & Co. during the 2nd quarter worth approximately $33,000. Finally, Poehling Capital Management INC. increased its holdings in Organon & Co. by 1.3% during the 1st quarter. Poehling Capital Management INC. now owns 219,288 shares of the company’s stock valued at $1,314,000 after purchasing an additional 2,796 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.

About Organon & Co.

Organon & Co is a global healthcare company focused primarily on women’s health, biosimilars and a portfolio of established medicines. The company develops, manufactures and commercializes prescription products designed to address a range of health needs, with an emphasis on expanding access to treatments in markets around the world.

Its women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as medicines used in areas including fertility and reproductive health.